Format

Send to

Choose Destination
Int J Cancer. 2018 Jul 1;143(1):190-198. doi: 10.1002/ijc.31295. Epub 2018 Feb 16.

The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study.

Author information

1
Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
2
Faculty of Health Sciences, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
3
Faculty of Health Sciences, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
4
Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
5
Department of Oncology, McGill University, Montreal, Quebec, Canada.
6
Department of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canada.

Abstract

Preclinical studies suggest statins may help prevent prostate cancer (PC), but epidemiologic results are mixed. Many epidemiological studies have relatively short prediagnosis drug exposure data, which may miss some statin use. We completed a nested case-control study investigating the impact of statin use on PC diagnosis and clinically significant PC using data from men aged ≥40 years in the Canadian province of Saskatchewan between 1990 and 2010. Drug exposure histories were derived from a population-based prescription drug database. We used conditional logistic regression to model use of statins as a class and stratified analyses for groups defined by lipophilicity. Clinically significant PC was defined as Gleason score 8-10 OR stage C or D or III or IV at diagnosis. 12,745 cases of PC were risk-set matched on age and geographic location to 50,979 controls. Greater than 90% of subjects had prediagnosis drug exposure histories >15 years. 2,064 (16.2%) cases and 7,956 (15.6%) controls were dispensed one or more statin prescriptions. In multivariable models, ever prescription of statins was not associated with PC diagnosis (OR 0.97; 95% CI 0.90-1.05). Neither lipophilic statins (OR 0.96, 95% CI 0.88-1.04) nor hydrophilic statins (OR 1.06, 95% CI 0.95-1.20) impacted PC diagnosis. There was no effect of the dose or duration of statin use. Diagnosis of clinically significant PC decreased with statin use (OR 0.84, 95% CI 0.73-0.97). Statin use is not associated with overall PC risk, regardless of duration or dose of statin exposure. Statin use is associated with a decreased risk of clinically significant PC.

KEYWORDS:

chemoprevention; epidemiology; pharmacoepidemiology; prostate cancer; statins

PMID:
29405283
DOI:
10.1002/ijc.31295
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center